| P2093 | author name string | Li Zhang | |
| | Jing Huang | |
| | Qiang Zhang | |
| | Yong Lin | |
| | Xiaoli Zhu | |
| | Siqing Sun | |
| P2860 | cites work | RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. | Q54581852 |
| | Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer | Q59274335 |
| | Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site | Q79190472 |
| | Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer | Q84734389 |
| | Microtubule-binding agents: a dynamic field of cancer therapeutics | Q27690249 |
| | Cancer statistics, 2010 | Q27860525 |
| | Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 |
| | ERCC1 isoform expression and DNA repair in non-small-cell lung cancer | Q30580553 |
| | Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis | Q33286793 |
| | Clinical perspectives on platinum resistance | Q33948747 |
| | RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis | Q34010393 |
| | The BATTLE trial: personalizing therapy for lung cancer | Q34275011 |
| | Gene expression from bronchoscopy obtained tumour samples as a predictor of outcome in advanced inoperable lung cancer | Q34358385 |
| | DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy | Q34564091 |
| | Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer | Q35000906 |
| | Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis | Q35510634 |
| | ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer | Q36230656 |
| | Evaluation of the quality of prognosis studies in systematic reviews | Q36426632 |
| | First line chemotherapy in advanced or metastatic NSCLC. | Q36522767 |
| | Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality | Q36864786 |
| | Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer | Q36951721 |
| | Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? | Q37073084 |
| | Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer | Q37809438 |
| | Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis | Q37981433 |
| | Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis | Q40337704 |
| | Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology | Q43207273 |
| | Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). | Q43660215 |
| | The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy | Q43742480 |
| | Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes | Q45189915 |
| | Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. | Q45304360 |
| | Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene | Q46593186 |
| | Processing of a psoralen DNA interstrand cross-link by XPF-ERCC1 complex in vitro | Q46897838 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| | chemotherapy | Q974135 |
| | non-small-cell lung carcinoma | Q3658562 |
| P304 | page(s) | 839-846 | |
| P577 | publication date | 2014-08-14 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer | |
| P478 | volume | 74 | |